skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Bexarotene (Code C1635)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Bexarotene

Definition: A synthetic retinoic acid agent with potential antineoplastic, chemopreventive, teratogenic and embryotoxic properties. Bexarotene selectively binds to and activates retinoid X receptors (RXRs), thereby inducing changes in gene expression that lead to cell differentiation, decreased cell proliferation, apoptosis of some cancer cell types, and tumor regression. (NCI04)

NCI-GLOSS Definition: A drug used to treat skin problems caused by cutaneous T-cell lymphoma that have not gotten better after other treatment. It is also being studied in the treatment of other types of cancer. Bexarotene is a type of retinoid.

Display Name: Bexarotene

Label: Bexarotene

NCI Thesaurus Code: C1635 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C0765273  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
3-methyl TTNEB
4-[1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl]benzoic Acid

External Source Codes: 
CAS Registry Number 153559-49-0 (see NLM ChemIDplus info)
FDA UNII Code A61RXM4375
ChEBI ID CHEBI:50859 (see ChEBI info)
PDQ Closed Trial Search ID 42117
PDQ Open Trial Search ID 42117 (check for NCI PDQ open clinical trial info)
UMLS CUI C0765273

Other Properties:
     Name Value (qualifiers indented underneath)
Accepted_Therapeutic_Use_For Oral or topical treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL).
Chemical_Formula C24H28O2
code C1635
Contributing_Source CTRP
Contributing_Source FDA
Legacy_Concept_Name Bexarotene
Semantic_Type Organic Chemical
Semantic_Type Pharmacologic Substance

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom